RxDoctor Payments Data

David Kleinman, MD

Ophthalmology · Rochester, NYNPI 1568457752

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $729,067 of the $730,065 with a category attached, or 99.9%. GSK accounts for 87.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $171,872 and has fallen 55.4% since, to $76,629 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$730,065in general payments, 2019–2025

Across 159 payments — averaging $4591.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$639K
  • Blueprint Medicines Corporation$47K
  • Emergent Biosolutions Inc.$17K
  • Sanofi$14K
  • Kala Pharmaceuticals, Inc.$8K
  • Coherus Oncology, Inc.$5K
  • plus $393 from 2 others

What the payments were for

  • Consulting fees$729,067100%
  • Speaking & faculty fees$2400%
  • Travel & lodging$5880%
  • Food & beverage$1700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$730,065 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$24,594
Medicare patients
85
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate15$506

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →